Delivery Order SPE2DB24D2010-SPE2DB25FABGF
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on April 24, 2025, for the supply of Ibrance 100 mg capsules (21-count packages) valued at $8,122.48. This firm fixed-price, non-competitive set-aside contract is scheduled for completion by May 15, 2025, and will be performed at the contractor's Conshohocken facility. The award is funded through the Defense Logistics Agency's Medical Supply Chain, which...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,247.92 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count packaging) under a firm fixed price contract. The contract was competitively awarded without a set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on September 5, 2025, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Ibrance 125 mg capsules (21-count packages). The contract, valued at $16,236.16, was awarded on June 20, 2025, with a completion date of July 14, 2025, under a firm fixed-price delivery order arrangement. This is a non-set-aside award, indicating it was competitively procured. The work will be...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABGFDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $16,244.96 by the Defense Logistics Agency on September 17, 2025, for the supply of Ibrance 100 mg capsules (21-count packages). The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award. Performance will be completed at the contractor's Conshohocken facility by October 8, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The Defense Logistics Agency's Medical Supply Chain relies on AmerisourceBergen's extensive portfolio to distribute critical pharmaceuticals and medical supplies across the Department of Defense and federal healthcare systems. Ibrance, a specialty oncology medication, represents the type of specialized pharmaceutical commodity that the contractor regularly supplies through its prime indefinite delivery vehicle. AmerisourceBergen's demonstrated capability to fulfill federal medical procurement requirements through open competition, combined with its significant contractual relationship with DLA, positions the company as a key vendor for supporting military and veteran healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/17/25 |